Cancer
Malignant Gastric Neoplasm
CI-CAN-00001130Explore in graph →
Top-level650 active trials4 approved drugs55 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00001130Explore in graph →
Clinical trials
2,844 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (232)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07085273 | Irinotecan Liposome II + 5-FU/LV + Oxaliplatin + Karelizumab in Neoadjuvant Treatment of Gastric Cancer | not yet recruiting | Phase 2 | 33 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 0 | Jul 31, 2025 | clinicaltrials |
| NCT06732856 | A Phase Ib/II Trial of Neoadjuvant Zolbetuximab Plus Docetaxel, Oxaliplatin and S-1 Chemotherapy in Patients With Locally Advanced Gastric Cancer(NEO-CLAUD) | recruiting | Phase 1 / Phase 2 | 57 | Asan Medical CenterOTHER |
| 1 |
| Jul 28, 2025 |
| clinicaltrials |
| NCT03421288 | Study of Atezolizumab + FLOT vs. FLOT Alone in Patients With GC/GEJ and High Immune Responsiveness(DANTE) | active not recruiting | Phase 2 | 677 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 2 | Jul 25, 2025 | clinicaltrials |
| NCT06427252 | The Efficacy and Safety of HIPEC Combined With PD-1 and SOX Chemotherapy for the Translational Treatment of GC or EGJC With PM | active not recruiting | Phase 2 | 50 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jul 16, 2025 | clinicaltrials |
| NCT04592211 | Pembrolizumab, Olaparib, Recurrent/Advanced Gastric and Gastro-esophageal Junction(GEJ) Cancer | recruiting | Phase 1 / Phase 2 | 71 | Yonsei UniversityOTHER | 1 | Jul 11, 2025 | clinicaltrials |
| NCT05894824 | T-Dxd in Combination With Ramucirumab as HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma | recruiting | Phase 1 / Phase 2 | 58 | Yonsei UniversityOTHER | 1 | Jul 11, 2025 | clinicaltrials |
| NCT05086692 | A Beta-only IL-2 ImmunoTherapY Study(ABILITY-1) | recruiting | Phase 1 / Phase 2 | 115 | Medicenna Therapeutics, Inc.INDUSTRY | 7 | Jul 9, 2025 | clinicaltrials |
| NCT07050524 | Omega-3 Supplementation and Immunotherapy in Gastric Cancer: A Phase II Trial | not yet recruiting | Phase 2 | 80 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jul 3, 2025 | clinicaltrials |
| NCT03093688 | Clinical Safty and Efficacy Study of Infusion of iNKT Cells and CD8+T Cells in Patients With Advanced Solid Tumor | recruiting | Phase 1 / Phase 2 | 40 | Shanghai Public Health Clinical CenterOTHER_GOV | 1 | Jul 2, 2025 | clinicaltrials |
| NCT06895447 | Robotic Gastrectomy for Locally Advanced Gastric Cancer After Neoadjuvant Therapy | recruiting | Phase 2 | 40 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jul 1, 2025 | clinicaltrials |
| NCT07045805 | Phase II Study of QL1706 Combined With Paclitaxel and Bevacizumab for Second-Line Immune Rechallenge in Gastric Cancer | not yet recruiting | Phase 2 | 66 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 0 | Jul 1, 2025 | clinicaltrials |
| NCT03175224 | APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors(SPARTA) | recruiting | Phase 2 | 497 | Apollomics Inc.INDUSTRY | 11 | Jun 27, 2025 | clinicaltrials |
| NCT06766305 | QL1706 Combined With SOX Used in Theperioperative Treatment | recruiting | Phase 1 / Phase 2 | 54 | Xiangdong ChengOTHER | 1 | Jun 17, 2025 | clinicaltrials |
| NCT07018063 | Neoadjuvant Nab-Paclitaxel Plus Oxaliplatin, S-1, and Sintilimab in Early-Onset Resectable Gastric Cancer(YOUNG-NEOS) | not yet recruiting | Phase 2 | 35 | zhoujingOTHER | 1 | Jun 12, 2025 | clinicaltrials |
| NCT02678182 | Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial(PLATFORM) | active not recruiting | Phase 2 | 494 | Royal Marsden NHS Foundation TrustOTHER | 1 | Jun 10, 2025 | clinicaltrials |
| NCT04581473 | Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection | active not recruiting | Phase 1 / Phase 2 | 192 | CARsgen Therapeutics Co., Ltd.INDUSTRY | 1 | Jun 5, 2025 | clinicaltrials |
| NCT06998771 | JSKN003 Combined Treatment of HER2-positive Gastric Cancer | not yet recruiting | Phase 2 | 153 | Shanghai JMT-Bio Inc.INDUSTRY | 0 | May 31, 2025 | clinicaltrials |
| NCT06157996 | Lenvatinib Plus Tislelizumab and CapeOX as First-Line Treatment for Advanced GC/GEJC With Positive PD-L1 and Low TMEscore | recruiting | Phase 2 | 92 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | May 30, 2025 | clinicaltrials |
| NCT06980389 | Node-Sparing Short-Course Radiotherapy Plus First-Line Therapy and PD-1 Inhibitor in Unresectable/Metastastic pMMR/MSS Gastric Cancer (MODIFI-GC) | not yet recruiting | Phase 2 | 176 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | May 20, 2025 | clinicaltrials |
| NCT06742411 | XELOX Combined With Sintilimab and HBO for Advanced or Metastatic GC/GEJC | recruiting | Phase 1 / Phase 2 | 57 | West China HospitalOTHER | 1 | May 7, 2025 | clinicaltrials |
| NCT06028737 | Total Neoadjuvant FLOT Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer(OCTASUR) | recruiting | Phase 2 / Phase 3 | 150 | Ukrainian Society of Clinical OncologyOTHER | 2 | May 6, 2025 | clinicaltrials |
| NCT06957977 | A Randomized Controlled Study of Endoscopic Cryoablation Combined With PD-1 Inhibitor for Maintenance Therapy in Advanced Gastric Cancer | not yet recruiting | Phase 2 | 42 | Zhongguang Luo, MDOTHER | 1 | May 6, 2025 | clinicaltrials |
| NCT06759233 | Endoscopic Cryoablation Combined With PD-1 in Advanced Gastric Cancer | not yet recruiting | Phase 2 | 15 | Zhongguang Luo, MDOTHER | 1 | Apr 29, 2025 | clinicaltrials |
| NCT06940921 | SBRT-LDRT-Cadonilimab for Advanced Gastric, Colorectal and Ovarian Cancers With Peritoneal Metastases | active not recruiting | Phase 1 / Phase 2 | 26 | Zhang TaoOTHER | 1 | Apr 27, 2025 | clinicaltrials |
| NCT06942767 | Combination of QLS31905, QL2107 and Chemotherapy as First-line Therapy in CLDN18.2-positive Unresectable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma | not yet recruiting | Phase 2 | 100 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Apr 27, 2025 | clinicaltrials |
| NCT06942663 | Randomized Phase II Trial Evaluating DFS in The Absence of an Adjuvant Component of Perioperative Chemotherapy in Patients With Gastric Cancer(JAGC1) | not yet recruiting | Phase 2 | 228 | Nizhny Novgorod Regional Clinical Oncology CenterOTHER_GOV | 0 | Apr 24, 2025 | clinicaltrials |
| NCT06685887 | A Clinical Study Evaluating the Efficacy of Systemic Chemotherapy and Immune Checkpoint Inhibitors Combined With Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Gastric Cancer Patients With Peritoneal Metastasis | recruiting | Phase 2 | 34 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Apr 11, 2025 | clinicaltrials |
| NCT04166721 | WaKING: Wnt and checKpoint INhibition in Gastric Cancer | active not recruiting | Phase 1 / Phase 2 | 52 | Royal Marsden NHS Foundation TrustOTHER | 1 | Apr 6, 2025 | clinicaltrials |
| NCT04802876 | Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors(ACROPOLI) | active not recruiting | Phase 2 | 184 | SOLTI Breast Cancer Research GroupOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT06888037 | Fruquintinib Combined With PD-1 Inhibitor as First-line Maintenance Therapy for Advanced Gastric Cancer | not yet recruiting | Phase 2 | 55 | Ruijin HospitalOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT06881017 | Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping | not yet recruiting | Phase 2 | 140 | China Medical University, ChinaOTHER | 0 | Mar 18, 2025 | clinicaltrials |
| NCT06871527 | Fruquintinib Combined With PD-1 Inhibitor and FOLFOX as First-Line Treatment For Advanced Gastric Cancer | not yet recruiting | Phase 1 / Phase 2 | 44 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Mar 12, 2025 | clinicaltrials |
| NCT01924819 | Trial of Preoperative Therapy for Gastric and Esophagogastric Junction Adenocarcinoma(TOPGEAR) | active not recruiting | Phase 2 / Phase 3 | 574 | Australasian Gastro-Intestinal Trials GroupNETWORK | 10 | Mar 4, 2025 | clinicaltrials |
| NCT05319639 | Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab | recruiting | Phase 1 / Phase 2 | 51 | Fujian Cancer HospitalOTHER_GOV | 1 | Feb 27, 2025 | clinicaltrials |
| NCT06405113 | FMT+SOX+Sintilimab As First-line Treatment for Advanced Gastric Cancer | recruiting | Phase 2 | 198 | Changzhou No.2 People's HospitalOTHER | 1 | Feb 20, 2025 | clinicaltrials |
| NCT05586061 | First-line Treatment with RC48 Plus Tislelizumab and S-1(RCTS) in Advanced Gastric Cancer(RCTS) | active not recruiting | Phase 2 | 55 | Qilu Hospital of Shandong UniversityOTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT06782412 | Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types(FAPIDO) | recruiting | Phase 2 / Phase 3 | 109 | KU LeuvenOTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT06791083 | Clinical Study of Envafolimab Combined With Fruquintinib and Chemotherapy for Neoadjuvant Treatment of Gastric Cancer | recruiting | Phase 2 | 40 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | Jan 24, 2025 | clinicaltrials |
| NCT06791148 | Low-dose Radiotherapy Combined With Chemotherapy and AK112 as Second-line Treatment in Patients With Advanced G/GEJ Cancer | recruiting | Phase 2 | 45 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Jan 24, 2025 | clinicaltrials |
| NCT06792162 | PD-1 Antibody Carilizumab Combined with Apatinib for Unresectable Stage III and IV DMMR Gastric Cancer | recruiting | Phase 2 | 20 | Peking University Third HospitalOTHER | 1 | Jan 24, 2025 | clinicaltrials |
| NCT06776770 | A Phase Ib/II Study of Adebrelimab in Combination with Capecitabine and Oxaliplatin in Cancer(GC-Ib/II) | recruiting | Phase 1 / Phase 2 | 52 | Cancer Hospital Chinese Academy of Medical Science, Shenzhen CenterOTHER | 1 | Jan 15, 2025 | clinicaltrials |
| NCT06422403 | A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers(VALUE-CHECK) | recruiting | Phase 2 | 360 | National University Hospital, SingaporeOTHER | 1 | Jan 10, 2025 | clinicaltrials |
| NCT04404595 | Claudin18.2 CAR-T (CT041) in Patients With Gastric, Pancreatic Cancer, or Other Specified Digestive Cancers | active not recruiting | Phase 1 / Phase 2 | 110 | CARsgen Therapeutics Co., Ltd.INDUSTRY | 2 | Jan 8, 2025 | clinicaltrials |
| NCT03368963 | TAS102 in Combination With NAL-IRI in Advanced GI Cancers | active not recruiting | Phase 1 / Phase 2 | 64 | Emory UniversityOTHER | 1 | Jan 7, 2025 | clinicaltrials |
| NCT06054906 | Neoadjuvant of Sintilimab Combined Weekly Metronomic Chemotherapy (PLOF) for Resectable Locally Advanced Gastric Cancer | recruiting | Phase 2 | 50 | Huashan HospitalOTHER | 1 | Dec 30, 2024 | clinicaltrials |
| NCT06748508 | Comparing the Efficacy of Sintilimab Plus Nab-POF Regimen, Sintilimab Plus XELOX Chemotherapy, and Lenvatinib, Sintilimab Plus XELOX Chemotherapy in the Treatment of HER2-negative, Metastatic Gastric Cancer(FDZL-GC003) | not yet recruiting | Phase 2 | 141 | Fudan UniversityOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT06706895 | A Single-arm, Single-center Phase II Clinical Study on the Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection Combined With Fruquintinib Capsules in the Second-line Treatment of Patients With Advanced Gastric Cancer | not yet recruiting | Phase 2 | 21 | Shanghai Zhongshan HospitalOTHER | 0 | Nov 27, 2024 | clinicaltrials |
| NCT06697366 | Liposomal Irinotecan Combined with Sintilimab for Second-line Treatment of Progressive Gastric Cancer | not yet recruiting | Phase 2 | 27 | Ruijin HospitalOTHER | 0 | Nov 20, 2024 | clinicaltrials |
| NCT06532799 | TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Stomach and Esophageal Cancer(BAH250) | recruiting | Phase 1 / Phase 2 | 75 | Essen BiotechOTHER | 1 | Nov 12, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Jul 31, 2025source: clinicaltrials